Related Experiment Video
Updated: Apr 10, 2026

09:25
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
19.2K
Cardiac Angiosarcoma in a 17-Year-Old Female: A Rare Case Report and Literature Review
Martin Nguyen1, Tai Nguyen2, Thao Pham3
1Radiology, West Virginia School of Osteopathic Medicine, Lewisburg, USA.
Cureus
|September 2, 2025
Summary
Primary cardiac angiosarcoma is a rare and aggressive cancer in young patients. This case highlights diagnostic challenges and poor prognosis, emphasizing the need for new treatments for this rare cardiac tumor.
Area of Science:
- Cardiovascular Pathology
- Pediatric Oncology
- Medical Imaging
Background:
- Primary cardiac angiosarcoma is exceptionally rare in pediatric populations (0-18 years).
- The condition often presents with vague symptoms and has an aggressive nature, leading to a poor prognosis.
- Early diagnosis is frequently delayed due to nonspecific symptoms like cough and dyspnea.
Observation:
- A 17-year-old female presented with persistent dry cough and orthopnea.
- Echocardiography revealed a large pericardial effusion; CT and MRI identified a right atrial mass with extensive metastatic disease, including liver and skull lesions.
- Liver biopsy confirmed metastatic angiosarcoma with characteristic immunohistochemical markers (CD31, CD34, CD117; Ki-67 40%).
Findings:
- Despite six months of chemotherapy (paclitaxel and gemcitabine), the patient showed disease progression with new metastatic sites.
- The angiosarcoma demonstrated aggressive behavior with rapid progression and widespread metastasis.
- Histopathology and immunohistochemistry were crucial for confirming the diagnosis of cardiac angiosarcoma.
Implications:
- This case underscores the critical need for high clinical suspicion in young patients with unexplained cardiopulmonary symptoms.
- Current treatment strategies, including chemotherapy and surgery, offer limited efficacy for advanced cardiac angiosarcoma.
- There is an urgent requirement for developing novel therapeutic strategies to improve outcomes for this rare and aggressive malignancy.

